Fortress Biotech, Inc. (FBIO)
FBIO moved a median of -0.68% 30 minutes after news, and -0.59% by the close. How FBIO actually reacts to news — the realized, point-in-time move the market made, measured across 235 labeled events over the last three years with zero look-ahead.
FBIO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.37% | 35% | 234 |
| 30-min | -0.68% | 37% | 235 |
| 60-min | -0.86% | 37% | 235 |
| to close | -0.59% | 44% | 235 |
| Middle 50% of FBIO reactions | -2.59% to +0.99% |
|---|---|
| Median reaction (30-min) | -0.68% |
| Measured reactions | 235 |
Half of all Fortress Biotech, Inc. news events land between -2.59% and +0.99% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How FBIO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | -0.89% | 39% | -1.54% |
| Analyst downgrades | 13 | -0.95% | 39% | -1.64% |
| Rating reiterations | 16 | +0.98% | 69% | +0.90% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how FBIO ranks against every other measured name →
That’s how FBIO usually reacts — get an email when it moves on news →Email me when FBIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to FBIO's baseline. Nothing else.
Recent FBIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Fortress Biotech, Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.40% | |
| Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | -0.15% | +0.74% | |
| Form 10-Q Fortress Biotech, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.48% | +0.34% | |
| Form 8-K Fortress Biotech, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -5.48% | +0.34% | |
| Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | -5.48% | +0.34% | |
| Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing | Press release | GlobeNewswire | +1.79% | -2.68% | |
| Form 8-K Fortress Biotech, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -1.26% | |
| Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference | Press release | GlobeNewswire | +2.49% | +2.90% | |
| Form 10-Q Fortress Biotech, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.13% | +2.55% | |
| Form 8-K Fortress Biotech, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -2.13% | +2.55% | |
| Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | -2.13% | +2.55% | |
| Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference | Press release | GlobeNewswire | +2.16% | +2.59% | |
| Form DEF 14A Fortress Biotech, Inc. For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | -0.89% | -1.77% | |
| Form DEFA14A Fortress Biotech, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.89% | -1.77% | |
| Form 10-K Fortress Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.91% | -10.18% | |
| Form 8-K Fortress Biotech, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +2.91% | -10.18% | |
| Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | +2.91% | -10.18% | |
| Form 8-K Fortress Biotech, Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | +3.33% | |
| Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million | Press release | GlobeNewswire | -0.37% | +3.33% | |
| Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease | Press release | GlobeNewswire | +1.45% | -9.21% | |
| Form 8-K Fortress Biotech, Inc. For: Feb 22 | SEC filing · Form 8-K | SEC EDGAR | +1.45% | -9.21% | |
| Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million | Press release | GlobeNewswire | +1.45% | -9.21% | |
| UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million | Press release | GlobeNewswire | +1.45% | -9.21% | |
| Form 8-K Fortress Biotech, Inc. For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -7.33% | -6.02% | |
| Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States | Press release | GlobeNewswire | -7.33% | -6.02% | |
| Form EFFECT Fortress Biotech, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.41% | -3.77% | |
| Form S-1 Fortress Biotech, Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.31% | +7.34% | |
| Form 8-K Fortress Biotech, Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | +7.34% | |
| Form 8-K Fortress Biotech, Inc. For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | +2.33% | +10.67% | |
| Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission | Press release | GlobeNewswire | +2.33% | +10.67% | |
| Form 8-K Fortress Biotech, Inc. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -1.70% | -1.51% | |
| Form 10-Q Fortress Biotech, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.81% | +6.07% | |
| Form 8-K Fortress Biotech, Inc. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | +6.07% | |
| Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | +0.81% | +6.07% | |
| Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout | Press release | GlobeNewswire | -0.73% | +1.47% | |
| Form 8-K Fortress Biotech, Inc. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | +2.81% | |
| Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 | Press release | GlobeNewswire | +0.25% | +2.81% | |
| Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing | Press release | GlobeNewswire | +0.25% | +2.81% | |
| Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | -0.03% | +9.56% | |
| Form 10-Q Fortress Biotech, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.96% | +4.43% | |
| Form 8-K Fortress Biotech, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -2.96% | +4.43% | |
| Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | -2.96% | +4.43% | |
| Form 8-K Fortress Biotech, Inc. For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | -0.52% | |
| Form 8-K Fortress Biotech, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -1.12% | -4.47% | |
| Form 8-K Fortress Biotech, Inc. For: May 30 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | +5.26% | |
| Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | Press release | GlobeNewswire | -2.09% | -1.05% | |
| Form 10-Q Fortress Biotech, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.22% | +0.56% | |
| Form 8-K Fortress Biotech, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -2.22% | +0.56% | |
| Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | -2.22% | +0.56% | |
| Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference | Press release | GlobeNewswire | -2.83% | -2.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the FBIO section they belong to.
Where else FBIO is measured.
FBIO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Retractable Technologies, Inc. (RVP) | 237 | 0.00% | 45% |
| Assembly Biosciences, Inc. (ASMB) | 236 | -0.01% | 41% |
| Rockwell Medical, Inc. (RMTI) | 235 | +0.40% | 57% |
| Equillium, Inc. (EQ) | 234 | 0.00% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Fortress Biotech, Inc.'s median reaction calculated?
Every labeled FBIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 235 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of FBIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does FBIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.